Nevertheless, it is essential to establish whether exercise-induced physiological irisin concentrations can improve cholesterol homeostasis to a degree that would be effective in targeting atherogenic dyslipidaemia as a component of MetS or if supraphysiological levels must be achieved pharmacologically. The gene discussed is FNDC5; the disease is metabolic syndrome.